These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

448 related items for PubMed ID: 24646861

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.
    Floege J, Covic AC, Ketteler M, Mann J, Rastogi A, Spinowitz B, Rakov V, Lisk LJ, Sprague SM.
    Nephrol Dial Transplant; 2017 Nov 01; 32(11):1918-1926. PubMed ID: 28339993
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.
    Greig SL, Plosker GL.
    Drugs; 2015 Apr 01; 75(5):533-42. PubMed ID: 25761962
    [Abstract] [Full Text] [Related]

  • 9. Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study.
    Covic AC, Sprague SM, Rastogi A, Ketteler M, Walpen S, Perrin A, Floege J.
    Nephron; 2020 Apr 01; 144(9):428-439. PubMed ID: 32585670
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy and Safety of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in Chinese Dialysis Patients with Hyperphosphataemia: A Randomised, Open-Label, Multicentre, 12-Week Phase III Study.
    Liu J, Zuo L, Walpen S, Bernard L, Marty M, Enoiu M.
    Nephron; 2024 Apr 01; 148(1):22-33. PubMed ID: 37473746
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and Safety of Ferric Citrate on Hyperphosphatemia among Chinese Patients with Chronic Kidney Disease Undergoing Hemodialysis: A Phase III Multicenter Randomized Open-Label Active-Drug-Controlled Study.
    Wang Y, Chen X, Zhu H, Guo Z, Yang Y, Luo P, He Y, Xu Y, Ji D, Gao X, Sun X, Xing C, Wang Y, Wang X, Zhao S, Guan Y, Lin H, Zhong A, Shui H, Shao F, Lv L, Yan Y, Sun X, Zhang L.
    Am J Nephrol; 2023 Apr 01; 54(11-12):479-488. PubMed ID: 37812931
    [Abstract] [Full Text] [Related]

  • 13. Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients.
    Sprague SM, Ketteler M, Covic AC, Floege J, Rakov V, Walpen S, Rastogi A.
    Hemodial Int; 2018 Oct 01; 22(4):480-491. PubMed ID: 29656600
    [Abstract] [Full Text] [Related]

  • 14. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN, Lewis JB, Dwyer JP, Greene T, Middleton J, Sika M, Umanath K, Abraham JD, Arfeen SS, Bowline IG, Chernin G, Fadem SZ, Goral S, Koury M, Sinsakul MV, Weiner DE, Collaborative Study Group.
    Am J Kidney Dis; 2015 Sep 01; 66(3):479-88. PubMed ID: 25958079
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.
    Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, Chertow GM, Hirakata H.
    Nephrol Dial Transplant; 2014 May 01; 29(5):1053-60. PubMed ID: 24376274
    [Abstract] [Full Text] [Related]

  • 17. A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis.
    Bousher A, Al-Makki A, Sutton J, Shepler B.
    Clin Ther; 2014 Dec 01; 36(12):2082-2093. PubMed ID: 25450474
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride.
    Chen JB, Chiang SS, Chen HC, Obayashi S, Nagasawa M, Hexham JM, Balfour A, Junge G, Akiba T, Fukagawa M.
    Nephrology (Carlton); 2011 Nov 01; 16(8):743-50. PubMed ID: 21854503
    [Abstract] [Full Text] [Related]

  • 19. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease.
    Geisser P, Philipp E.
    Clin Nephrol; 2010 Jul 01; 74(1):4-11. PubMed ID: 20557860
    [Abstract] [Full Text] [Related]

  • 20. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.
    Ketteler M, Sprague SM, Covic AC, Rastogi A, Spinowitz B, Rakov V, Walpen S, Floege J.
    Nephrol Dial Transplant; 2019 Jul 01; 34(7):1163-1170. PubMed ID: 29846719
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.